Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter
Key facts
- Where
- Solna, SwedenSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04856488, who can take part
Where in Sweden
- Karolinska University HospitalSolna, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jan Calissendorff
- Trial code
- NCT04856488EU 2024-517110-15-00
- Record updated
- 10 February 2026
- Original description
The purpose of this study is to assess if preoperative treatment with Lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve palsyRead full original descriptionShow less
The purpose of this study is to assess if preoperative treatment with Lugol's solution prior to thyroidectomy can reduce the surgical complications hypoparathyroidism and laryngeal nerve palsy
Inclusion: Hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free T4 <30 pmol/L or Graves' disease; Signed informed consent.
Exclusion: Previous thyroid surgery; Treatment with steroids or anticoagulants; Unstable coronary artery disease; Congestive heart failure; Renal insufficiency; Hepatic failure; Current infection; Diabetes mellitus type 1; Active cancer; Severe psychiatric illness; Iodine hypersensitivity; Thyroid associated orbitopathy CAS > 2; Amiodarone treatment; Pregnancy; Breast feeding; Women of child bearing potential not using contraceptive; Inability to comprehend the meaning of the study.